Pharming Group to host webcast on findings of a new study published in Cell advancing functional classification of variants of uncertain significance (VUS) to improve APDS diagnosis ...

Anurag Relan, Pharming Chief Medical Officer, will lead a Q&A session with Dr. Milner and discuss next steps to collaborate with genetic testing laboratories on their VUS reclassification efforts ...

Anurag Relan, Pharming Chief Medical Officer, will lead a Q&A session with Dr. Milner and discuss next steps to collaborate with genetic testing laboratories on their VUS reclassification efforts, ...

A Columbia study addresses a key challenge in the diagnosis of rare genetic disorders.

Researchers identified variants which may cause activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) Results enable clinical genetic testing labs to appropriately reclassify VUSs ...

Mary Catchpole, 19, has the same life-threatening genetic condition, activated PI3-Kinase delta syndrome (APDS) ...

A teenager who lost her mother, aunt and uncle to a genetic condition has become the first person ... The list price for leniolisib is £352,000 per person per year but the company Pharming has agreed ...

A teenager who lost her mother, aunt and uncle to a genetic condition has become the first person in Europe to receive a ...

Angioedema Treatment Global Market Report 2025. The Business Research Company's Angioedema Treatment Global Market Report 2025 – Market Size, Trends, And ...

Despite its potential benefits, opposition to transgenic crops remains strong in influential European countries. This article explores the basis for this opposition and looks at its implications ...